Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127529 · ClinicalTrials.gov registry record
Ceprotin Treatment Registry
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 43
- Enrollment target
NCT01127529: Completed study, sponsored by Baxalta now part of Shire.
NCT01127529 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01127529 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
The overall objective is to collect and assess data on the treatment, safety, and treatment outcomes of subjects prescribed, receiving and participating in the Ceprotin treatment registry.
Interventions
- BIOLOGICAL Protein C Concentrate (Human)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-06-23 |
| Est. Completion | 2015-06-22 |
What the finished NCT01127529 record still lists
NCT01127529 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Protein C Concentrate (Human) is the first listed.
NCT01127529 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01127529 about?
NCT01127529 is a clinical study titled "Ceprotin Treatment Registry". The overall objective is to collect and assess data on the treatment, safety, and treatment outcomes of subjects prescribed, receiving and participating in the Ceprotin treatment registry.
What is the current status of trial NCT01127529?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2010-06-23. Estimated completion is 2015-06-22.
What interventions are being tested in trial NCT01127529?
The interventions under investigation include: Protein C Concentrate (Human) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01127529?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI